As of 2026-05-08, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -20.44 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.63 CAD, the upside of Briacell Therapeutics Corp is -463.05%.
Based on its market price of 5.63 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 463.05%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -20.44 - -20.44 | -20.44 | -463.05% |
| P/E | (27.96) - (17.17) | (24.63) | -537.5% |
| DDM - Stable | (36.36) - (99.74) | (68.05) | -1308.7% |
| DDM - Multi | (29.69) - (63.38) | (40.45) | -818.4% |
| Market Cap (mil) | 40.82 |
| Beta | 0.45 |
| Outstanding shares (mil) | 7.25 |
| Enterprise Value (mil) | 10.91 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.78% |
| Cost of Debt | 5.00% |
| WACC | 6.73% |